Publications
Journal Articles
                  Brosda, Sandra, Aoude, Lauren G., Bonazzi, Vanessa F., Patel, Kalpana, Lonie, James M., Belle, Clemence J., Newell, Felicity, Koufariotis, Lambros T., Addala, Venkateswar, Naeini, Marjan M., Simes, John, Walpole, Euan T., Mai, Gang T., Watson, David I., Karapetis, Chris S., Gebski, Val, Barnes, Elizabeth H., Oostendorp, Martijn, Wilson, Kate, Ackland, Stephen P., Shannon, Jenny, Marx, Gavin, Burge, Matthew, Finch, Robert, Thomas, Janine, Varma, Suresh, Nott, Louise, Pearson, John V., Krause, Lutz ... Barbour, Andrew P. (2024). Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy. Genome Medicine, 16 (1) 90, 90. doi: 10.1186/s13073-024-01362-z
                
              
                  Belle, Clemence J., Lonie, James M., Brosda, Sandra and Barbour, Andrew P. (2023). Tumour microenvironment influences response to treatment in oesophageal adenocarcinoma. Frontiers in Immunology, 14 1330635, 1-8. doi: 10.3389/fimmu.2023.1330635
                
              
                  Lonie, James M., Brosda, Sandra, Bonazzi, Vanessa F., Aoude, Lauren G., Patel, Kalpana, Brown, Ian, Sharma, Sowmya, Lampe, Guy, Addala, Venkateswar, Koufariotis, Lambros T., Wood, Scott, Waddell, Nicola, Dolcetti, Riccardo and Barbour, Andrew P. (2023). The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy – results from the AGITG DOCTOR trial and the cancer evolution biobank. Frontiers in Immunology, 14 1220129, 1-15. doi: 10.3389/fimmu.2023.1220129
                
              
                  Aoude, Lauren G., Brosda, Sandra, Ng, Jessica, Lonie, James M., Belle, Clemence J., Patel, Kalpana, Koufariotis, Lambros T., Wood, Scott, Atkinson, Victoria, Smithers, B. Mark, Pearson, John V., Waddell, Nicola, Barbour, Andrew P. and Bonazzi, Vanessa F. (2023). ctDNA: a promising biomarker for predicting recurrence in BRAF-negative melanoma patients. Journal of Molecular Diagnostics, 25 (10), 771-781. doi: 10.1016/j.jmoldx.2023.06.014
                
              
                  Bonazzi, Vanessa F., Aoude, Lauren G., Brosda, Sandra, Bradford, Julia J., Lonie, James M., Loffler, Kelly A., Gartside, Michael G., Patel, Kalpana, Mukhopadhyay, Pamela, Keane, Colm, Gebski, Val, Kench, James G., Goldstein, David, Waddell, Nicola, Barbour, Andrew P. and the Australasian Gastro‐Intestinal Trials Group (AGITG) GAP investigators (2023). C‐reactive protein is a prognostic biomarker in pancreatic ductal adenocarcinoma patients. Asia-Pacific Journal of Clinical Oncology, 21 (1), 77-86. doi: 10.1111/ajco.13993
                
              
                  Bonazzi, V. F., Aoude, L. G., Brosda, S., Lonie, J. M., Patel, K., Bradford, J. J., Koufariotis, L. T., Wood, S., Smithers, B. Mark, Waddell, N. and Barbour, A. P. (2022). ctDNA as a biomarker of progression in oesophageal adenocarcinoma. ESMO Open, 7 (3) 100452, 100452. doi: 10.1016/j.esmoop.2022.100452